Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Biedenbach DJ, Hackel MA, Quintana A, Wible M, Dowzicky MJ, McGovern PC, Bouchillon SK.

J Glob Antimicrob Resist. 2015 Dec;3(4):311-312. doi: 10.1016/j.jgar.2015.09.004. Epub 2015 Oct 22. No abstract available.

PMID:
27842883
2.

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Biedenbach DJ, Bouchillon SK, Johnson B, Alder J, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):1933-1939. Epub 2016 Sep 27.

PMID:
27677280
3.

Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.

Biedenbach DJ, Giao PT, Hung Van P, Su Minh Tuyet N, Thi Thanh Nga T, Phuong DM, Vu Trung N, Badal RE.

Clin Ther. 2016 Sep;38(9):2098-105. doi: 10.1016/j.clinthera.2016.07.172. Epub 2016 Sep 6.

PMID:
27612610
4.
5.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):194-9. doi: 10.1016/j.diagmicrobio.2016.07.012. Epub 2016 Jul 14.

PMID:
27461798
6.

Erratum to: In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study.

Biedenbach DJ, Badal RE, Huang MY, Motyl M, Singhal PK, Kozlov RS, Roman AD, Marcella S.

Infect Dis Ther. 2016 Sep;5(3):405. doi: 10.1007/s40121-016-0120-3. No abstract available.

7.

Discrepancy between genotypic and phenotypic extended-spectrum β-lactamase rates in Escherichia coli from intra-abdominal infections in the USA.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Med Microbiol. 2016 Sep;65(9):905-9. doi: 10.1099/jmm.0.000307. Epub 2016 Jul 8.

PMID:
27392786
8.

In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study.

Biedenbach DJ, Badal RE, Huang MY, Motyl M, Singhal PK, Kozlov RS, Roman AD, Marcella S.

Infect Dis Ther. 2016 Jun;5(2):139-53. doi: 10.1007/s40121-016-0112-3. Epub 2016 Jun 10. Erratum in: Infect Dis Ther. 2016 Sep;5(3):405.

9.

Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DF.

Clin Ther. 2016 Jun;38(6):1510-1521. doi: 10.1016/j.clinthera.2016.04.035. Epub 2016 May 24.

PMID:
27234360
10.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

11.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

12.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

13.

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2849-57. doi: 10.1128/AAC.02286-15. Print 2016 May.

14.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.

15.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.

Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1385-92. doi: 10.1128/AAC.01870-15.

16.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1067-78. doi: 10.1128/AAC.02379-15. Print 2016 Feb.

17.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.

Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.

PMID:
26541881
18.

In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF.

J Antimicrob Chemother. 2016 Jan;71(1):162-9. doi: 10.1093/jac/dkv311. Epub 2015 Oct 26.

PMID:
26503667
19.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.

20.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.

21.

Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries.

Kresken M, Körber-Irrgang B, Biedenbach DJ, Batista N, Besard V, Cantón R, García-Castillo M, Kalka-Moll W, Pascual A, Schwarz R, Van Meensel B, Wisplinghoff H, Seifert H.

Clin Microbiol Infect. 2016 Jan;22(1):63.e1-63.e5. doi: 10.1016/j.cmi.2015.08.019. Epub 2015 Aug 29.

22.

Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Glob Antimicrob Resist. 2015 Sep;3(3):190-197. doi: 10.1016/j.jgar.2015.05.005. Epub 2015 Jul 6.

PMID:
27873708
23.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

24.

In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.

25.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.

Surg Infect (Larchmt). 2015 Jun;16(3):298-304. doi: 10.1089/sur.2014.060. Epub 2015 Apr 20.

PMID:
25894976
26.

Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF.

Antimicrob Agents Chemother. 2015;59(6):3606-10. doi: 10.1128/AAC.05186-14. Epub 2015 Mar 23.

27.

In vitro susceptibility of Gram-negative isolates from patients with urinary tract infections in Vietnam: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Thi Thanh Nga T, Thi Lan Phuong T, My Phuong T, Mai Phuong D, Biedenbach DJ, Narang P, Giao Phan T, Badal RE.

J Glob Antimicrob Resist. 2014 Dec;2(4):338-339. doi: 10.1016/j.jgar.2014.04.003. Epub 2014 May 23. No abstract available.

PMID:
27873699
28.

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P.

J Glob Antimicrob Resist. 2014 Sep;2(3):179-182. doi: 10.1016/j.jgar.2014.03.002. Epub 2014 Mar 26.

PMID:
27873726
29.

Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).

Biedenbach DJ, Bouchillon SK, Hoban DJ, Hackel M, Phuong DM, Nga TT, Phuong NT, Phuong TT, Badal RE.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):463-7. doi: 10.1016/j.diagmicrobio.2014.05.009. Epub 2014 May 17.

PMID:
24923210
30.

Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study.

Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M.

Clin Ther. 2014 Jun 1;36(6):953-60. doi: 10.1016/j.clinthera.2014.04.003. Epub 2014 May 15.

PMID:
24835558
31.

In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P, Mokaddas E.

Diagn Microbiol Infect Dis. 2014 May;79(1):54-9. doi: 10.1016/j.diagmicrobio.2014.01.017. Epub 2014 Jan 30.

PMID:
24582580
32.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

Morrissey I, Bouchillon SK, Hackel M, Biedenbach DJ, Hawser S, Hoban D, Badal RE.

J Med Microbiol. 2014 Apr;63(Pt 4):556-61. doi: 10.1099/jmm.0.068981-0. Epub 2014 Jan 29.

PMID:
24478449
33.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
34.

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.

Mendes RE, Alley MR, Sader HS, Biedenbach DJ, Jones RN.

Antimicrob Agents Chemother. 2013 Jun;57(6):2849-57. doi: 10.1128/AAC.00160-13. Epub 2013 Mar 18.

35.

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Cantón R, Paterson DL.

Int J Antimicrob Agents. 2013 Mar;41(3):224-8. doi: 10.1016/j.ijantimicag.2012.10.014. Epub 2013 Jan 8.

PMID:
23305657
36.

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.

Biedenbach DJ, Turner LL, Jones RN, Farrell DJ.

Diagn Microbiol Infect Dis. 2012 Oct;74(2):204-6. doi: 10.1016/j.diagmicrobio.2012.06.006. Epub 2012 Jul 21.

PMID:
22819604
37.

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.

Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN.

Int J Antimicrob Agents. 2012 Apr;39(4):321-5. doi: 10.1016/j.ijantimicag.2011.11.016. Epub 2012 Feb 4.

PMID:
22306239
38.

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN.

J Antimicrob Chemother. 2012 May;67(5):1170-5. doi: 10.1093/jac/dks001. Epub 2012 Jan 27.

PMID:
22287234
39.

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.

Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2012 Mar;56(3):1619-23. doi: 10.1128/AAC.05789-11. Epub 2012 Jan 9.

40.

Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.

Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK, Jones RN.

Diagn Microbiol Infect Dis. 2011 Dec;71(4):415-20. doi: 10.1016/j.diagmicrobio.2011.08.011. Epub 2011 Oct 5.

PMID:
21982563
41.

JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.

Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN.

Antimicrob Agents Chemother. 2011 Jul;55(7):3631-4. doi: 10.1128/AAC.00162-11. Epub 2011 May 9.

42.

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.

Farrell DJ, Putnam SD, Biedenbach DJ, Moro L, Bozzella R, Celasco G, Jones RN.

Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.

43.

Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.

Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2010 Dec;68(4):459-67. doi: 10.1016/j.diagmicrobio.2010.09.018.

PMID:
21094428
44.

Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.

Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M.

Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021.

PMID:
21075602
45.

Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.

Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR.

Antimicrob Agents Chemother. 2010 Oct;54(10):4518-9. doi: 10.1128/AAC.00235-10. Epub 2010 Jul 26. No abstract available.

46.

Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.

Biedenbach DJ, Castanheira M, Jones RN.

Antimicrob Agents Chemother. 2010 Sep;54(9):4009-11. doi: 10.1128/AAC.01812-09. Epub 2010 Jul 12.

47.

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Biedenbach DJ, Ross JE, Putnam SD, Jones RN.

Antimicrob Agents Chemother. 2010 May;54(5):2273-5. doi: 10.1128/AAC.00090-10. Epub 2010 Mar 22. No abstract available.

48.

Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.

Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN.

Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7.

PMID:
20211548
49.

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).

Biedenbach DJ, Rhomberg PR, Mendes RE, Jones RN.

Diagn Microbiol Infect Dis. 2010 Mar;66(3):301-7. doi: 10.1016/j.diagmicrobio.2009.10.014.

PMID:
20159376
50.

Binaphthyl-based dicationic peptoids with therapeutic potential.

Bremner JB, Keller PA, Pyne SG, Boyle TP, Brkic Z, David DM, Garas A, Morgan J, Robertson M, Somphol K, Miller MH, Howe AS, Ambrose P, Bhavnani S, Fritsche TR, Biedenbach DJ, Jones RN, Buckheit RW Jr, Watson KM, Baylis D, Coates JA, Deadman J, Jeevarajah D, McCracken A, Rhodes DI.

Angew Chem Int Ed Engl. 2010;49(3):537-40. doi: 10.1002/anie.200904392. No abstract available.

PMID:
20014083

Supplemental Content

Loading ...
Support Center